Xipamide: no advantage over bendrofluazide in hypertension

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Nephrology

Background:

• Uncontrolled hypertension remains a significant global health challenge.
• Diuretics are a cornerstone of antihypertensive therapy.
• Optimizing diuretic combinations is crucial for effective blood pressure management.

Purpose of the Study:

• To evaluate the additive antihypertensive effect of xipamide when combined with bendrofluazide in patients with uncontrolled hypertension.
• To assess the impact of this combination therapy on serum potassium and blood urea levels.

Main Methods:

• A clinical study involving patients with uncontrolled hypertension.
• Addition of xipamide 20 mg daily to existing bendrofluazide 5 mg daily regimen.
• Monitoring of blood pressure, serum potassium, and blood urea concentrations.

Main Results:

• No significant additive antihypertensive effect was observed with the addition of xipamide.
• Clinically important blood pressure response was excluded by 95% confidence limits.
• Xipamide treatment significantly worsened hypokalemia (low potassium).
• Blood urea concentration was significantly increased by xipamide treatment.

Conclusions:

• Combination therapy with xipamide and bendrofluazide is not effective for additional blood pressure lowering in hypertensive patients.
• This combination poses risks of electrolyte imbalance (hypokalemia) and renal function impairment (increased blood urea).
• Alternative therapeutic strategies should be considered for patients with uncontrolled hypertension inadequately managed by bendrofluazide alone.